Citalopram 10mg tablets

Nchi: Uingereza

Lugha: Kiingereza

Chanzo: MHRA (Medicines & Healthcare Products Regulatory Agency)

Viambatanisho vya kazi:

Citalopram hydrobromide

Inapatikana kutoka:

Actavis UK Ltd

ATC kanuni:

N06AB04

INN (Jina la Kimataifa):

Citalopram hydrobromide

Kipimo:

10mg

Dawa fomu:

Oral tablet

Njia ya uendeshaji:

Oral

Darasa:

No Controlled Drug Status

Dawa ya aina:

Valid as a prescribable product

Bidhaa muhtasari:

BNF: 04030300; GTIN: 5012617017390

Taarifa za kipeperushi

ACTAVIS LOGO
CITALOPRAM 10MG, 20MG AND 40MG FILM-COATED TABLETS
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, please ask your doctor, pharmacist
or nurse.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.

If you get any of the side effects, talk to your doctor, pharmacist or
nurse. This includes
any possible side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Citalopram tablets are and what they are used for
2.
What you need to know before you take Citalopram tablets
3.
How to take Citalopram tablets
4.
Possible side effects
5.
How to store Citalopram tablets
6.
Contents of the pack and other information
1.
WHAT CITALOPRAM TABLETS ARE AND WHAT THEY ARE USED FOR
Citalopram belongs to a group of antidepressants called selective
serotonin reuptake inhibitors
(SSRI’s).
Citalopram is used for the treatment of depressive illnesses (major
depressive episodes).
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE CITALOPRAM TABLETS
DO NOT TAKE CITALOPRAM TABLETS:

if you are ALLERGIC to citalopram or any of the other ingredients of
this medicine (listed
in section 6)

if you are taking MAO (MONOAMINE OXIDASE) INHIBITORS (medicines used
for treatment
of depression or Parkinson’s disease). The MAO-inhibitor called
selegiline may be used
in combination with citalopram, but only at doses of less than 10mg
per day

if you have RECENTLY TAKEN MAO-INHIBITORS. Depending on the type of
MAO-inhibitor
you used to use, you may have to wait for up to 14 days after stopping
the MAO-
inhibitor before starting with Citalopram. If you stop taking
Citalopram and want to start
using MAO-inhibitors, you have to wait for at least 7 days. Please ask
your doctor for
advice.

if you are taking LINEZOLID unless you are under close me

Tabia za bidhaa

OBJECT 1
CITALOPRAM 10MG TABLETS
Summary of Product Characteristics Updated 09-Jan-2020 | Accord-UK Ltd
•
1. Name of the medicinal product
•
2. Qualitative and quantitative composition
•
3. Pharmaceutical form
•
4. Clinical particulars
•
4.1 Therapeutic indications
•
4.2 Posology and method of administration
•
4.3 Contraindications
•
4.4 Special warnings and precautions for use
•
4.5 Interaction with other medicinal products and other forms of
interaction
•
4.6 Fertility, pregnancy and lactation
•
4.7 Effects on ability to drive and use machines
•
4.8 Undesirable effects
•
4.9 Overdose
•
5. Pharmacological properties
•
5.1 Pharmacodynamic properties
•
5.2 Pharmacokinetic properties
•
5.3 Preclinical safety data
•
6. Pharmaceutical particulars
•
6.1 List of excipients
•
6.2 Incompatibilities
•
6.3 Shelf life
•
6.4 Special precautions for storage
•
6.5 Nature and contents of container
•
6.6 Special precautions for disposal and other handling
•
7. Marketing authorisation holder
•
8. Marketing authorisation number(s)
•
9. Date of first authorisation/renewal of the authorisation
•
10. Date of revision of the text
1. Name of the medicinal product
Citalopram 10 mg Tablets
2. Qualitative and quantitative composition
Citalopram 10mg Tablets: 1 film-coated tablet contains 12.495 mg
citalopramhydrobromide, equivalent to 10
mg Citalopram.
For the full list of excipients, see section 6.1
3. Pharmaceutical form
Film-coated tablet
Round, white tablets with a diameter of 6 mm.
4. Clinical particulars
4.1 Therapeutic indications
Treatment of depressive illness in the initial phase and as
maintenance against potential relapse/recurrence.
Citalopram is also indicated in the treatment of panic disorder with
or without agoraphobia.
4.2 Posology and method of administration
Posology
Major Depressive Episodes
_Adults:_
Citalopram should be administered as a single oral dose of 20 mg
daily.
Dependent on individual patient response, the dose may be increased to
a maximum of 40 mg da